On 13 April 2017, Roche entered a licensing agreement with Bristol Myers Squibb (BMS) for the license of the anti-myostatin adnectin BMS-986089.

The agreement meant Roche would pay BMS an upfront payment of $170 million with the potential of milestone payment of $205 million. Biogen have also entered a licensing agreement with BMS for the anti-eTau compound which is phase II ready for potential in Alzheimer’s Disease and progressive supranuclear palsy (PSP). Licensing assets to both Biogen and Roche means that BMS will be able to prioritise other potential opportunities for asset development for their portfolio.

Figure 1 shows a comparable number between licensing and partnership deals within Duchenne Muscular Dystrophy.

However, figure 2 shows over the last five years a growth in the number of licensing deals occurring in the Duchenne Muscular Dystrophy space year by year meaning this is a strong area providing companies with opportunities for asset development for the future.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.